Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Donna Ching

Hilo, HI Medical Doctor

NPI 1780636670 CMS profile 307959

73 Puuhonu Pl, Suite 200, Hilo, HI 96720

Open in the dashboard

General payments

$3,785

166 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Donna Ching of Hilo, HI is reported in the CMS Open Payments database as having received $3,785 across 166 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $523 21
2024 General $330 19
2023 General $383 14
2022 General $881 46
2021 General $884 40
2020 General $311 14
2019 General $473 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donna Ching
  • Hawaii median
  • Middle half of Hawaii
  • National median

In program year 2025, general payments to Donna Ching were reported at $523. Among 3,634 Hawaii profiles paid that year, the median was $183 and the middle half received between $63 and $652.

Show as a table
Year Donna Ching Hawaii median Middle half National median
2019 $473 $190 $62–$622 $163
2020 $311 $125 $43–$352 $114
2021 $884 $150 $51–$524 $132
2022 $881 $172 $58–$577 $149
2023 $383 $166 $61–$537 $160
2024 $330 $172 $59–$611 $164
2025 $523 $183 $63–$652 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $827 16 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $567 31 payments
  3. ITI, Inc. $370 13 payments
  4. Pfizer Inc. $336 27 payments
  5. Janssen Pharmaceuticals, Inc $306 10 payments
  6. Amgen Inc. $306 14 payments
  7. Avanir Pharmaceuticals, Inc. $215 5 payments
  8. Otsuka America Pharmaceutical, Inc. $198 8 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $148 15 payments
  10. Biohaven Pharmaceuticals, Inc. $123 14 payments
  11. Other $388 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,785 166 payments
Products named General payments · program years 2019–2025
  1. Ozempic $727 14 payments
  2. TRINTELLIX $539 29 payments
  3. NURTEC ODT Pain $336 27 payments
  4. ZAVZPRET $331 26 payments
  5. CAPLYTA $325 11 payments
  6. NURTEC ODT Primary Care $270 29 payments
  7. NUEDEXTA $215 5 payments
  8. XARELTO $204 8 payments
  9. RYBELSUS $201 6 payments
  10. REXULTI $181 7 payments
  11. Other $1,264 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

166 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record